New scan could spot prostate cancer spread better than current test
Diagnosis
Not yet recruiting
This phase 2 trial tests whether a new radioactive imaging agent, 61Cu-NU101, can detect prostate cancer spread as well as or better than the current standard, Pylarify. 34 men with confirmed prostate cancer and visible disease on a prior Pylarify scan will receive one dose of 61…
Phase: PHASE2 • Sponsor: Hoag Memorial Hospital Presbyterian • Aim: Diagnosis
Last updated Jun 27, 2026 13:05 UTC